Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex, Inc. (NASDAQ: GNPX) has initiated the recruitment of clinical trial sites for the Acclaim-2 trial, targeting late-stage non-small cell lung cancer (NSCLC) patients. This Phase 1/2 open-label trial will examine the combination of REQORSA™ immunogene therapy and Merck's Keytruda in patients with low PD-L1 expression. Approximately 150 patients at around 15 sites will be enrolled in this adaptive trial. The protocol may be adjusted based on investigator feedback, aiming to provide new treatment options for NSCLC patients.
Genprex, Inc. (NASDAQ: GNPX) announced its President and CEO, Rodney Varner, will participate in a weekly webinar series hosted by CEO Roadshow from April 22 to June 10, 2021.
The webinars will occur every Thursday from 11-11:30 a.m. EDT, providing an overview of the company and its gene therapy developments for cancer and diabetes. Attendees can ask questions after each presentation, and replays will be available on the company's website. Genprex focuses on innovative therapies, notably its lead candidate REQORSA™ for non-small cell lung cancer.
Genprex, Inc. (NASDAQ: GNPX) has been awarded the inaugural "License of the Year" from the University of Pittsburgh Innovation Institute for its diabetes gene therapy, GPX-002. This therapy aims to convert pancreas alpha cells into insulin-producing beta-like cells, potentially curing diabetes. Preclinical results show promise with mice, indicating blood glucose levels normalized for up to four months. The award recognizes the innovative work of Dr. George Gittes at UPMC, enhancing the company's reputation in gene therapy.
Genprex, Inc. (GNPX) announced promising preclinical data for its TUSC2 immunogene therapy (REQORSA™) presented at the AACR 2021 meeting. The data indicate that REQORSA, combined with chemotherapy and immunotherapies, enhances treatment efficacy for non-small cell lung cancer (NSCLC), particularly in cases resistant to existing therapies. Upcoming Acclaim-1 and Acclaim-2 clinical trials aim to explore these combinations further. The research highlights REQORSA's potential to address unmet needs in NSCLC treatment.
Genprex, Inc. (NASDAQ: GNPX) announces that Michael Redman, its Executive VP and COO, will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean from April 6-9, 2021. This event will feature over 80 company presentations and more than 50 expert panel discussions focusing on advancements in cell and gene therapy. Genprex aims to develop innovative therapies for cancer and diabetes, with its lead product candidate, REQORSA™, currently evaluated for non-small cell lung cancer. Registration is available for credentialed investors and media.
Genprex has announced that preclinical data on TUSC2 immunogene therapy (REQORSA™) will be presented at the AACR 21 meeting from April 9-14, 2021. This therapy aims to improve treatment outcomes for non-small cell lung cancer (NSCLC) by enhancing the efficacy of chemotherapy and overcoming resistance to osimertinib. The upcoming Acclaim-1 and Acclaim-2 clinical trials will evaluate REQORSA in combination with AstraZeneca’s Tagrisso® and Merck's Keytruda®. The presentations are expected to attract attention from leading cancer researchers.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Spring 2021 Oncology Investor Conference from March 29 to April 2, 2021. President and CEO Rodney Varner will deliver a virtual company overview on March 29 at 2 p.m. EDT, focusing on innovative gene therapies for non-small cell lung cancer and diabetes. Genprex's lead candidate, REQORSA™, has received Fast Track Designation by the FDA for treating NSCLC in combination with osimertinib, aiming to improve treatment options for patients with limited alternatives.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in two investor conferences in March 2021. The events are the Sachs 14th Annual European Life Sciences CEO Forum, taking place from March 10-12, and the 33rd Annual Roth Conference from March 15-17. Presentations will be led by CEO Rodney Varner, with availability for one-on-one meetings with investors. The presentations will be available for replay on the company's website following the events.
Genprex, Inc. (NASDAQ: GNPX) has announced a registered direct offering of 4,000,000 shares of common stock at $6.25 per share to institutional investors. The offering, priced at-the-market under Nasdaq rules, is expected to close on or around February 11, 2021, pending customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for this deal. No warrants will be issued. The company aims to utilize the funds to advance its clinical-stage gene therapy programs, specifically targeting cancers and diabetes.
Genprex, a clinical-stage gene therapy company focused on cancer and diabetes, has established a Clinical Advisory Board (CAB) to support its oncology and diabetes programs. This board is composed of leading clinical specialists who will guide the development of Genprex’s REQORSA™ immunogene therapy for non-small cell lung cancer and its diabetes gene therapy. CEO Rodney Varner emphasized the importance of the CAB's expertise in advancing clinical trials. Notable members include Dr. Michael Morse from Duke University and Dr. George E. Peoples, a veteran in cancer vaccine development.